Skip to main content
ArticleOPEN ACCESS

Indolent and mantle cell NHL: The future is BRIGHT

Blood
DOI: 10.1182/blood-2014-03-562124
0Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Flinn et al report a phase 3 study demonstrating similar complete response rates with bendamustine and rituximab compared with rituximab plus cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) in untreated indolent and mantle cell lymphomas. © 2014 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Fowler, N. (2014, May 8). Indolent and mantle cell NHL: The future is BRIGHT. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2014-03-562124

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free